The authors note further analysis may be needed to explore the prognostic factors that will assist clinicians in identifying patients who may benefit from early baricitinib treatment.
You Might Also Like
Explore This IssueSeptember 2019
Also By This Author
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
- Fleischmann R, Schiff M, Kvien TK, et al. Early vs. delayed start of baricitinib in patients with rheumatoid arthritis in a phase 3 trial of patients naive to methotrexate treatment. Ann Rheum Dis. 2019 Jun;78 (suppl 2):306.